

Table S1. Chemokine concentrations in blood plasma samples from patients infected with ancestral Wuhan strain of SARS-CoV-2 (COVID-19), n=56; and healthy donors (HD), n=51. Concentrations presented in pg/ml.

Chemokine	COVID-19, n = 56 Median (Q25-Q75)	HD, n = 51 Median (Q25-Q75)	COVID-19 vs. HD p-value
CCL2/MCP-1	636.8 (458.5-951.8)	208.5 (180.2-373.5)	<0.0001
CCL3/MIP-1 α	58.8 (38.7-326.4)	8.631 (6.1-30.7)	<0.0001
CCL4/MIP-1 β	22.91 (17.2-28.2)	16.7 (12.5-22.5)	0.0087
CCL7/MCP-3	26.1 (14.8-36.3)	10.4 (6.0-24.7)	0.0004
CCL11/Eotaxin	175.4 (121.1-355.2)	80.61 (55.10-105.8)	<0.0001
CCL22/MDC	629.8 (513.8-749.8)	873.5 (497.4-1265)	0.0005
CXCL1/GRO α	79.4 (55.1-115.4)	22.2 (9.4-46.4)	<0.0001
CXCL8/IL-8	18.5 (15.5-27.3)	3.2 (2.2-5.9)	<0.0001
CXCL9/MIG	3985.0 (7677.1-15917.8)	1161 (364.0-1959)	<0.0001
CXCL10/IP-10	31238.0 (3213.5-40000.0)	278.1 (147.9-451.9)	<0.0001
CX3CL1/Fractalkine	286.1 (202.3-393.5)	135.0 (73.23-274.8)	<0.0001

Table S2. Chemokine concentrations in blood plasma samples from patients infected with Alpha variant of SARS-CoV-2 (COVID-19), n=95; and healthy donors (HD), n=51. Concentrations presented in pg/ml.

Chemokine	COVID-19, n = 95 Median (Q25-Q75)	HD, n = 51 Median (Q25-Q75)	COVID-19 vs. HD p-value
CCL2/MCP-1	430.9 (254.3-706.8)	208.5 (180.2-373.5)	<0.0001
CCL3/MIP-1 α	51.0 (40.3-62.3)	8.631 (6.1-30.7)	0.0002
CCL4/MIP-1 β	24.8 (21.7-30.7)	16.7 (12.5-22.5)	<0.0001
CCL7/MCP-3	53.8 (39.8-70.1)	10.4 (6.0-24.7)	<0.0001
CCL11/Eotaxin	90.7 (65.8-118.6)	80.61 (55.10-105.8)	ns
CCL22/MDC	474.1 (424.2-722.2)	873.5 (497.4-1265)	0.0067
CXCL1/GRO α	37.67 (25.7-67.8)	22.2 (9.4-46.4)	0.004
CXCL8/IL-8	12.7 (7.9-20.7)	3.2 (2.2-5.9)	<0.0001
CXCL9/MIG	5896.0 (3661.1-8790.2)	1161 (364.0-1959)	<0.0001
CXCL10/IP-10	3142.1 (1004.1-40000.0)	278.1 (147.9-451.9)	<0.0001
CX3CL1/Fractalkine	404.3 (273.9-549.7)	135.0 (73.23-274.8)	<0.0001

Table S3. Chemokine concentrations in blood plasma samples from patients infected with Delta variant of SARS-CoV-2 (COVID-19), n=78; and healthy donors (HD), n=51. Concentrations presented in pg/ml.

Chemokine	COVID-19, n = 78 Median (Q25-Q75)	HD, n = 51 Median (Q25-Q75)	COVID-19 vs. HD p-value
CCL2/MCP-1	562.8 (319.0-779.3)	208.5 (180.2-373.5)	<0.0001
CCL3/MIP-1 α	11.59 (8.4-17.21)	8.631 (6.1-30.7)	ns
CCL4/MIP-1 β	16.3 (12.5-20.2)	16.7 (12.5-22.5)	ns
CCL7/MCP-3	16.8 (12.7-27.2)	10.4 (6.0-24.7)	ns
CCL11/Eotaxin	51.0 (40.0-75.3)	80.61 (55.10-105.8)	0.0001
CCL22/MDC	344.1 (247.2-461.9)	873.5 (497.4-1265)	<0.0001
CXCL1/GRO α	25.7 (15.5-56.9)	22.2 (9.4-46.4)	ns
CXCL8/IL-8	7.6 (3.9-16.1)	3.2 (2.2-5.9)	<0.0001
CXCL9/MIG	2303.0 (1232.1-4459.0)	1161 (364.0-1959)	<0.0001
CXCL10/IP-10	18488.0 (7084.2-53108.1)	278.1 (147.9-451.9)	<0.0001
CX3CL1/Fractalkine	119.2 (88.2-161.8)	135.0 (73.23-274.8)	ns

Table S4. Chemokine concentrations in blood plasma samples from patients infected with Omicron variant of SARS-CoV-2 (COVID-19), n=57; and healthy donors (HD), n=51. Concentrations presented in pg/ml.

Chemokine	COVID-19, n=57 Median (Q25-Q75)	HD, n = 51 Median (Q25-Q75)	COVID-19 vs. HD p-value
CCL2/MCP-1	434.6 (286.9-628.9)	208.5 (180.2-373.5)	<0.0001
CCL3/MIP-1 α	13.35 (9.5-17.3)	8.631 (6.1-30.7)	ns
CCL4/MIP-1 β	22.4 (17.9-28.3)	16.7 (12.5-22.5)	0.0012
CCL7/MCP-3	18.5 (13.5-23.9)	10.4 (6.0-24.7)	ns
CCL11/Eotaxin	65.2 (54.6-88.7)	80.61 (55.10-105.8)	ns
CCL22/MDC	306.1 (252.6-455.5)	873.5 (497.4-1265)	<0.0001
CXCL1/GRO α	27.33 (14.9-49.1)	22.2 (9.4-46.4)	ns
CXCL8/IL-8	6.5 (4.3-10.5)	3.2 (2.2-5.9)	<0.0001
CXCL9/MIG	3000.0 (1507.1-5951.2)	1161 (364.0-1959)	<0.0001
CXCL10/IP-10	1506.1 (592.8-3194.2)	278.1 (147.9-451.9)	<0.0001
CX3CL1/Fractalkine	137.0 (104.1-188.)	135.0 (73.23-274.8)	ns